Relmada Therapeutics (RLMD) Free Cash Flow (2012 - 2026)
Relmada Therapeutics (RLMD) reported Free Cash Flow of -$15.1 million for Q1 2026, up 16.6% year-over-year from -$12.9 million in Q1 2025, and down 3.23% quarter-over-quarter from -$14.6 million in Q4 2025.
Relmada Therapeutics (RLMD) Free Cash Flow (2012 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has 15 years of Free Cash Flow data on file, last reported at -$15.1 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$15.1 million, up 16.6% year-over-year; the trailing twelve-month figure through Mar 2026 was -$42.8 million (up 24.65% YoY), and the FY2025 annual result was -$45.8 million, up 11.53% from the prior year.
- Free Cash Flow declined to -$15.1 million in Q1 2026 per RLMD's latest filing, from -$14.6 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$6.4 million in Q2 2025 and troughed at -$35.9 million in Q4 2022.
- A 5-year average of -$15.8 million and a median of -$14.6 million in 2025 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Free Cash Flow soared 71.44% in 2023, then plunged 65.87% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$35.9 million in 2022, then soared by 71.44% to -$10.2 million in 2023, then increased by 14.15% to -$8.8 million in 2024, then slumped by 65.87% to -$14.6 million in 2025, then fell by 3.23% to -$15.1 million in 2026.
- Business Quant data shows RLMD's Free Cash Flow at -$15.1 million in Q1 2026, -$14.6 million in Q4 2025, and -$6.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Relmada Therapeutics | 581.07 Mn | 581.07 Mn | - | -15.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.07 Mn |
| Mar 31, 2026 | -15.07 Mn |
| Dec 31, 2025 | -14.60 Mn |
| Dec 31, 2025 | -14.60 Mn |
| Sep 30, 2025 | -6.72 Mn |
| Sep 30, 2025 | -6.72 Mn |
| Jun 30, 2025 | -6.40 Mn |
| Jun 30, 2025 | -6.40 Mn |
| Mar 31, 2025 | -18.07 Mn |
| Mar 31, 2025 | -18.07 Mn |
| Dec 31, 2024 | -8.80 Mn |
| Dec 31, 2024 | -8.80 Mn |
| Sep 30, 2024 | -16.66 Mn |
| Sep 30, 2024 | -16.66 Mn |
| Jun 30, 2024 | -13.26 Mn |
| Jun 30, 2024 | -13.26 Mn |
| Mar 31, 2024 | -13.04 Mn |
| Mar 31, 2024 | -13.04 Mn |
| Dec 31, 2023 | -10.25 Mn |
| Dec 31, 2023 | -10.25 Mn |